

## DAFTAR PUSAKA

1. Hunter P. *Tropical diseases and the poor: Neglected tropical diseases are a public health problem for developing and developed countries alike*. Oxford, UK: Backwell Publishing Ltd. 2014;2015(4):347–350.
2. Pangaribuan HR. Pengaruh Faktor Predisposisi, Pendukung, dan Pendorong terhadap Pencegahan Kecacatan Pasien Penderita Penyakit Kusta di RS Kusta Kabupaten Tobasa Tahun 2012. *Kebijakan, Promosi Kesehatan dan Biostatistik*: 2012;1(1).
3. WHO. *Leprosy: weekly epidemiological record*, September 2017. *World Health Organ Wkly Epidemiol Rec*. 2017;92(35):501-520.
4. Oktaria S, Hurif NS, Naim W, Thio HB, Nijsten TEC, Richardus JH. *Dietary diversity and poverty as risk factors for leprosy in Indonesia: A case-control study*. *PLoS Negl Trop Dis*; 2018;12(3):e0006317.
5. Kementerian Kesehatan. *Profil Kesehatan Indonesia 2017*. Jakarta: Kementerian Kesehatan Republik Indonesia: 2018.
6. Bennett BH, Parker DL, Robson M. *Leprosy: steps along the journey of eradication*. *Public Health Rep*. 2008;123(2):198-205.
7. Rodrigues LC, Lockwood DNJ. *Leprosy now: epidemiology, progress, challenges, and research gaps*. *Lancet Infect Dis*. 2011;11(6):464–470.
8. Kementerian Kesehatan Republik Indonesia. *Profil Kesehatan Indonesia Tahun 2013*. Jakarta: Kementerian Kesehatan Republik Indonesia: 2014.
9. Dinas Kesehatan Provinsi Sumatera Barat. *Profil Kesehatan Provinsi Sumatera Barat Tahun 2017*. Dinas Kesehatan Provinsi Sumatera Barat : 2018.
10. Pratamasari MA, Listiawan MY. *Retrospective Study: Type 1 Leprosy Reaction*. *BIKKK - Berk Ilmu Kesehatan Kulit dan Kelamin - Periodic Dermatology Venereology*. 2015;27:137–143.
11. Kamath S, Vaccaro SA, Rea TH, Ochoa MT. *Recognizing and managing the immunologic reactions in leprosy*. *J Am Acad Dermatol*. 2014;71(4):795-803.
12. Goulart IMB, Bernardes SDO, Marques CR, Pimenta VL, Gonçalves MA, Goulart LR. *Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts*. *Clin Vaccine Immunol*. 2008;15(1):101-105.

13. Scollard DM, Martelli CMT, Stefani MMA, De Fatima Maroja M, Villahermosa L, Pardillo F, et al. *Risk factors for leprosy reactions in three endemic countries*. Am J Trop Med Hyg. 2015;92(1):108-114.
14. Aisyah I, Agusni I, et al. Penelitian Retrospektif : Gambaran Pasien Baru Kusta (*A Retrospective Study : Profile of New Leprosy Patients*). 2015.
15. Vionni, Arifputra J. Reaksi Kusta. Cermin Dunia Kedokt. 2016;43(7):501–504.
16. Selum, Wahyuni CU. Risiko Kecacatan pada Ketidakteraturan Berobat Penderita Kusta di Kabupaten Pamekasan Provinsi Jawa Timur, Universitas Airlangga: Surabaya: The Indonesian Journal of Public Health. Maret 2012;8(3):117–121.
17. Sarkar J, Dasgupta A, Dutt D. *Disability among new leprosy patients, an issue of concern: An institution based study in an endemic district for leprosy in the state of West Bengal, India*. Indian J Dermatol Venereol Leprol 2012;78(3):328-334.
18. White C. *Clinical and Social Aspects of Leprosy (Hansen's Disease) and Contemporary Challenges to Elimination*. J Dermatolog Clin Res. 2017;5(2):2–4.
19. Soedarjatmi, Widagdo TIL. Faktor-faktor Yang Melatarbelakangi Persepsi Penderita Terhadap Stigma Penyakit Kusta. J Promosi Kesehat Indonesia: 2009;(4)1.
20. Paudel D, Sah BP, Bhandary S, Shilpakar SL, Chettri ST, Mishra S. *Isolated Leprosy of Pinna Masquerading Perichondritis : A Rarest Entity*. Am J Med Case Reports. Science and Education Publishing. 2014;2(4):87–89.
21. Idrissi BEN, Iyer AM, Ramaglia V, Rosa PS, Soares CT, Baas F, et al. *In Situ complement activation and T-cell immunity in leprosy spectrum: An immunohistological study on leprosy lesional skin*. Sreevatsan S, editor. PLoS One. 2017 May 15;12(5):e0177815.
22. Pinheiro RO, de Souza Salles J, Sarno EN, Sampaio EP. *Mycobacterium leprae–host-cell interactions and genetic determinants in leprosy: an overview*. Future Microbiol. 2011;6(2):217–230.

23. Cole ST, Singh P. *Leprosy : A Practical Guide : 1th edn*. Springer-Verlag: 2012.
24. Bhat RM, Prakash C. *Leprosy: An overview of pathophysiology*. Interdisciplinary Perspectives on Infectious Diseases. 2012.
25. Sales AM, Ponce de Leon A, Düppre NC, Hacker MA, Nery JAC, Sarno EN, et al. *Leprosy among patient contacts: A multilevel study of risk factors*. PLoS Negl Trop Dis. 2011;5(3):e1013.
26. Norlatifah, Sutomo AH dan S. Hubungan Kondisi Fisik Rumah, Sarana Air Bersih dan Karakteristik Masyarakat dengan Kejadian Kusta di Kabupaten Tapin Kalimantan Selatan. J Kesmas UAD: 2010.
27. Depkes RI, Buku Pedoman Nasional Pengendalian Penyakit Kusta, Departemen Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan, Jakarta. 2007.
28. Rambey MA. Hubungan Jenis Kelamin dengan Kejadian Cacat Tingkat 2 Pada Penderita Kusta di Kabupaten Lamongan tahun 2011-2012 (Thesis). FKM UI. 2012.
29. Pescarini JM, Strina A, Nery JS, Skalinski LM, de Andrade KVF, Penna MLF, et al. *Socioeconomic risk markers of leprosy in high-burden countries: A systematic review and meta-analysis*. Steinmann P, editor. PLoS Negl Trop. 2018 Jul 9;12(7):e0006622.
30. Nardi SMT, Ikehara E, Pedro HSP, Paschoal VDA. *Characterization of the profession/occupation of individuals affected by leprosy and the relationship with limitations in professional activities*. Indian J Lepr. 2012;84(1):1–8.
31. Prawoto. Faktor-faktor Risiko yang Berpengaruh Terjadinya Reaksi Kusta. Jurnal Epidemiologi. Semarang: 2008.
32. Zahra M, Bubakar AHA, Setiasih NL. *The Correlation of the Level of Community Knowledge and Education with the Level of Leprosy Occurrence in Central Jakarta Area year 2017*. Jcmro. 15Sep. 2018;1(06):29-33.
33. Warsini S. Faktor-faktor yang Mempengaruhi Penularan Kusta pada Kontak Serumah di Propinsi DIY dan Kabupaten Klaten (Thesis). Universitas Gadjah Mada: Yogyakarta: 2007.

34. Kerr-Pontes LRS, Barreto ML, Evangelista CMN, Rodrigues LC, Heukelbach J, Feldmeier H. *Socioeconomic, environmental, and behavioural risk factors for leprosy in North-east Brazil: results of a case-control study. Int J Epidemiol.* 2006 Aug 1;35(4):994–1000.
35. Zenha EMR, Wambier CG, Novelino AL, de Andrade TAM, Ferreira MAN, Frade MAC, et al. *Clinical and immunological evaluation after BCG-id vaccine in leprosy patients in a 5-year follow-up study. J Inflamm Res.* 2012 Dec 18;5:125–135.
36. International Leprosy Association (ILA) 2002. *Report of international leprosy association technical forum*, Paris: Februari 2002.
37. Goulart IMB, Bernardes Souza DO, Marques CR, Pimenta VL, Gonçalves MA, Goulart LR. *Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts. Clin Vaccine Immunol.* 2008;15(1):101-105.
38. Araujo S et al. *Molecular evidence for the aerial route of infection of Mycobacterium leprae and the role of asymptomatic carriers in the persistence of leprosy. Clin Infect Dis.* 2016;63(11):1412-1420.
39. Job CK, Jayakumar J, Kearney M, Gillis TP. *Transmission of leprosy: A study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg.* 2008;78(3):518-521.
40. Khumar BHKK. *IAL Textbook of Leprosy 2nd/2016.* Jaypee Brother Med Publ Ltd: India;2016.
41. Sehgal VN. *Textbook of Clinical Leprosy. 5<sup>th</sup> Revised Edition.* Jaypee Brothers Medical Publishers: India;2012.
42. WHO. *Enhanced global strategy for further reducing the disease burden due to leprosy: Operational Guideline 2011-2015. Lepr Rev.* 2014.
43. Warin AP. *Andrews' Diseases of the Skin: Clinical Dermatology: 12th edn.* Elsevier;2015.
44. Martodihardjo S, Susanto RSD. Reaksi Kusta dan Penanganannya. Dalam: Daili ES, Menaldi SL, Ismiarto SP, Nilasari H, penyunting. *Kusta. Edisi ke-2.* Jakarta. Balai Penerbit FKUI. 2003:75-82.

45. Van Brakel WH, Sihombing B, Djarir H, Beise K, Kusumawardhani L, Yulihane R, et al. *Disability in people affected by leprosy: the role of impairment, activity, social participation, stigma and discrimination. Glob Health Action.* 2012 Jul 20(5):10.3402/gha.v5i0.18394.
46. Moschioni C, Antunes CMDF, Grossi MAF, Lambertucci JR. *Risk factors for physical disability at diagnosis of 19,283 new cases of leprosy.* Rev Soc Bras Med Trop. 2010;43(1):19-22.
47. Aly'nsyah T, Lubis RS, Hutapea R. Karakteristik Pasien Kusta di Rumah Sakit Umum Pusat H. Adam Malik Medan Periode tahun 2009-2012. *Majalah Kedokteran Nusantara.* 2013;46(3):122-125.
48. Polycarpou A, Walker LS, Lockwood DNJ. *A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.* Front Immunol. 2017;8:23-33.
49. Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, et al. *Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy.* Clin Infect Dis. 2007;44:33-40.
50. Prameswari R, Listiawan MY, Prakoeswa CRS. Peran TNF- $\alpha$  pada Imunopatogenesis ENL dan Kontribusinya pada Penatalaksanaan ENL. *Berkala Ilmu Kesehatan Kulit & Kelamin.* 2012;24(1):43-48.
51. Umayana, Adi MS, Saraswati LD. Gambaran status kecacatan kusta pada penderita kusta Di Kabupaten Blora. *J Kesehat Masy.* 2016;4(4):496-502.
52. Putra IGND, Fauzi N, Agusni I. Kecacatan pada Penderita Kusta Baru di Divisi Kusta URJ Penyakit kulit dan Kelamin RSUD Dr. Soetomo Surabaya Periode 2004-2006. *Berkala Ilmu Kesehatan Kulit & Kelamin.* 2009;21(1):9-17.
53. Rismayanti R, Tandirerung J, Dwinata I, Ansar J. Faktor Risiko Kejadian Kecacatan Tingkat 2 Pada Penderita Kusta. *Media Kesehat Masy Indones.* 2017;13(1):51-7.
54. Rambey MA. Hubungan jenis kelamin dengan Kejadian cacat tingkat 2 pada penderita kusta di Kabupaten lamongan tahun 2011-2012. Tesis. 2012.

55. Nayak AK, Satheesh R, Shashidhar K. *Spectrum of physical deformities in leprosy patients visiting a tertiary care center in Mangalore*. Ann Trop Med Public Heal. 2017;1(10):22-26.
56. Ambade GR, Asia AJ, Tapre VN. *Trends And Types of Multiple Deformities in Leprosy: A Retrospective Study*. IOSR J Dent Med Sci. 2016;15(6):15-19.
57. Song et al. *Abnormalities in Stratum Corneum Function in Patients Recovered from Leprosy*. Skin Pharmacol Physiol. 2009;22(3):131-136.

